Fed. Circ. Affirms No Block On Amgen's Eye Med Biosimilar

By Theresa Schliep · March 14, 2025, 6:52 PM EDT

The Federal Circuit on Friday agreed with a lower court decision declining to temporarily block Amgen's biosimilar of Regeneron's blockbuster eye medication Eylea, affirming that court's application of claim construction precedent...

To view the full article, register now.